Cantor Fitzgerald Analysts Give Horizon Pharma PLC (HZNP) a $17.00 Price Target

Horizon Pharma PLC (NASDAQ:HZNP) received a $17.00 price target from Cantor Fitzgerald in a research report issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 29.38% from the company’s previous close.

A number of other research firms have also recently commented on HZNP. UBS AG set a $16.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Wednesday, June 7th. Zacks Investment Research upgraded Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. BMO Capital Markets reiterated a “buy” rating and set a $17.00 target price on shares of Horizon Pharma PLC in a research report on Friday, July 28th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, August 7th. Finally, Citigroup Inc. cut their target price on Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.46.

Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up 10.51% on Thursday, reaching $13.14. The company had a trading volume of 10,627,856 shares. The company has a 50 day moving average of $12.46 and a 200-day moving average of $13.55. The company’s market capitalization is $2.15 billion. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $23.24.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. Horizon Pharma PLC’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 EPS. Analysts predict that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.

Horizon Pharma PLC declared that its board has initiated a stock buyback program on Monday, May 8th that allows the company to buyback 1,000% of outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.

WARNING: “Cantor Fitzgerald Analysts Give Horizon Pharma PLC (HZNP) a $17.00 Price Target” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/17/cantor-fitzgerald-analysts-give-horizon-pharma-plc-hznp-a-17-00-price-target.html.

A number of institutional investors have recently added to or reduced their stakes in HZNP. BlackRock Inc. boosted its position in Horizon Pharma PLC by 1.8% in the second quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock valued at $160,247,000 after buying an additional 239,014 shares during the last quarter. Vanguard Group Inc. boosted its position in Horizon Pharma PLC by 1.8% in the second quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock valued at $154,105,000 after buying an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Horizon Pharma PLC by 119.4% in the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after buying an additional 3,409,411 shares during the last quarter. State Street Corp boosted its position in Horizon Pharma PLC by 12.0% in the second quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock valued at $58,241,000 after buying an additional 524,187 shares during the last quarter. Finally, Janus Capital Management LLC boosted its position in Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock valued at $65,173,000 after buying an additional 717,643 shares during the last quarter. Institutional investors own 83.75% of the company’s stock.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply